Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Virgile Tellier"'
Autor:
David Llères, Benoît Moindrot, Rakesh Pathak, Vincent Piras, Mélody Matelot, Benoît Pignard, Alice Marchand, Mallory Poncelet, Aurélien Perrin, Virgile Tellier, Robert Feil, Daan Noordermeer
Publikováno v:
Genome Biology, Vol 20, Iss 1, Pp 1-17 (2019)
Abstract Background Genomic imprinting is essential for mammalian development and provides a unique paradigm to explore intra-cellular differences in chromatin configuration. So far, the detailed allele-specific chromatin organization of imprinted ge
Externí odkaz:
https://doaj.org/article/6246306ae90347bbb877362b3c3099bb
Autor:
Mallory Poncelet, Mélody Matelot, Daan Noordermeer, Benoît Moindrot, Vincent Piras, Virgile Tellier, Robert Feil, Benoît Pignard, Aurélien Perrin, Rakesh Pathak, David Llères, Alice Marchand
Publikováno v:
Genome Biology
Genome Biology, 2019, 20 (1), pp.272. ⟨10.1186/s13059-019-1896-8⟩
Genome Biology, Vol 20, Iss 1, Pp 1-17 (2019)
Genome Biology, BioMed Central, 2019, 20 (1), pp.272. ⟨10.1186/s13059-019-1896-8⟩
Genome Biology, 2019, 20 (1), pp.272. ⟨10.1186/s13059-019-1896-8⟩
Genome Biology, Vol 20, Iss 1, Pp 1-17 (2019)
Genome Biology, BioMed Central, 2019, 20 (1), pp.272. ⟨10.1186/s13059-019-1896-8⟩
BackgroundGenomic imprinting is essential for mammalian development and provides a unique paradigm to explore intra-cellular differences in chromatin configuration. So far, the detailed allele-specific chromatin organization of imprinted gene domains
Autor:
Daan Noordermeer, Vincent Piras, Rakesh Pathak, Robert Feil, Alice Marchand, Virgile Tellier, Benoît Pignard, David Llères, Mélody Matelot, Benoît Moindrot, Mallory Poncelet, Aurélien Perrin
SUMMARYMammalian genomic imprinting is essential for development and provides a unique paradigm to explore intra-cellular differences in chromatin configuration. Here, we compared chromatin structure of the two conserved imprinted domains controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8a1bd138b2409f6f243944b9332b66
https://doi.org/10.1101/633065
https://doi.org/10.1101/633065
Autor:
Guillaume Beinse, Virgile Tellier, Valentin Charvet, Isabelle Borget, Christophe Massard, Antoine Hollebecque, Loic Verlingue
Publikováno v:
Cancer Research. 79:668-668
The industry and investigators’ communities are currently facing a conjunction of increasing number of anti-neoplastic agents (ANA) candidate for phase 1 clinical trials (P1CT) and an important attrition rate for final approval. Improvement of the